Why is the Atomo Diagnostics (ASX:AT1) share price wobbling on Thursday?

It's been a busy week so far for the medical devices company

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Atomo Diagnostics Ltd (ASX: AT1) share price has been struggling to gain traction today. It is currently trading flat at 30.5 cents — the same price it closed at yesterday.

It's been a similar story for most of the day, with the shares hitting a high of 32 cents earlier before retreating.

There has been no market-sensitive information out of the medical devices company today. However, the company has released a slew of price-sensitive information in the past few days.

Further – while not likely to have a meaningful impact on the Atomo Diagnostics share price – the company has also released its AGM address today.

Let's investigate further.

What's been happening with Atomo Diagnostics?

Atomo released its Q1 FY22 activities and earnings report on 25 October. In it, the company recognised a significant increase in revenue to $2.4 million, up 260% from the previous quarter.

Cash receipts totalled $2.2 million for the quarter, also a 206% gain from the last quarter.

Much of the growth in income stemmed from a "significant increase in Covid-19 rapid antigen test sales". The company sold more than 100,000 units compared to just 5,000 in FY21.

The company also signed an agreement with Access Bio for US$1.72 million to secure "up to 20 million Covid-19 rapid antigen tests".

The following day, Atomo released a key update regarding its HIV self-test. It said the Therapeutic Goods Administration (TGA) has "broadened the organisations to whom the HIV self-test can be applied".

This enables the company to supply its HIV self-test to any business, organisation, or institution (including a pharmacy) that has the proper training. Curiously, the varied conditions also allow the company to sell the test on pharmacy websites.

The decision also enables Atomo to advertise its HIV self-test in any form of media to be marketed in Australia.

Before these changes, Atomo said it was unable to advertise or promote its HIV self-test website or the HIV self-test product itself.

Despite these apparently positive changes, investors haven't piled into Atomo shares. Since its quarterly update on Monday night and HIV self-test announcement on Tuesday morning, the Atomo Diagnostics share price has sunk by around 13%.

News from the AGM

One other point worth mentioning is that Atomo also released the presentations from its AGM today. While not price-sensitive, investors were able to peer into the company's operations, its progress in FY21, and its future outlook.

In the report, Atomo explained it has "an opportunity to sell up to 20 million antigen tests during FY22–23".

It also sees itself capitalising on local Covid-19 opportunities, including a self-test product in this category as well.

Atomo Diagnositcs share price snapshot

It's been a difficult year to date for the Atomo Diagnostics share price, falling by 1.6%. It has also slumped by around 21% since the company listed on the ASX in April 2020.

For comparison, the S&P/ASX 200 index (ASX: XJO) has gained around 11% since the start of the year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »